Sign In
Buy DYAI
$0.785
+0.0029 (+0.371%)
At Close: Jun 22, 2026
An Interview with the President & COO: How Dyadic is Commercializing Its Protein Platform Across Multi-Billion-Dollar Markets
08:46am, Monday, 22'nd Jun 2026
SmallCaps Daily Sits Down with Joe Hazelton to Discuss Dyadic's Product Strategy, Strategic Partnerships, and Long-Term Growth Vision New York, New York--(Newsfile Corp. - June 22, 2026) - Dyadic Appl
JUPITER, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI), d/b/a Dyadic Applied BioSolutions (“Dyadic” or the “Company”), a biotechnology company focused on th
Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development
07:25am, Thursday, 28'th May 2026
JUPITER, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic,” “we,” “us,” “our,” or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a biot
Dyadic to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
04:05pm, Thursday, 21'st May 2026
JUPITER, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a glob
Company invites individual and institutional investors, as well as advisors and analysts, to attend this real-time, interactive presentation at the Skyline Signature Series™ Company invites individu
Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference
09:35am, Tuesday, 19'th May 2026
JUPITER, Fla. , May 19, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic," "we," "us," "our," or the "Company") (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology co
Dyadic International, Inc. (DYAI) Q1 2026 Earnings Call Transcript
04:40am, Thursday, 14'th May 2026
Dyadic International, Inc. (DYAI) Q1 2026 Earnings Call Transcript
Dyadic Announces First Quarter 2026 Financial Results and Highlights Recent Company Progress
04:05pm, Wednesday, 13'th May 2026
Received initial purchase orders for recombinant bovine transferrin from customers in the cultivated meat industry Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Bi
Dyadic to Report Q1 2026 Financial Results and Host Conference Call on Wednesday May 13, 2026
04:05pm, Wednesday, 29'th Apr 2026
JUPITER, Fla., April 29, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology co
Dyadic International, Inc. (DYAI) Q4 2025 Earnings Call Transcript
03:25am, Thursday, 26'th Mar 2026
Dyadic International, Inc. (DYAI) Q4 2025 Earnings Call Transcript
Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress
04:51pm, Wednesday, 25'th Mar 2026
Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic's production platform, with Dyadic eligible to receive a share of profits from product sales
Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices
07:20am, Monday, 16'th Mar 2026
JUPITER, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company produci
Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026
04:10pm, Wednesday, 11'th Mar 2026
JUPITER, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology co
Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)
07:20am, Wednesday, 04'th Mar 2026
JUPITER, Fla. and BENGALURU, India, March 04, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechn
Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milesto
